GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles

Archive ouverte

Pozzorini, Christian | Andre, Gregoire | Coletta, Tommaso | Buisson, Adrien | Bieler, Jonathan | Ferrer, Loïc | Kempfer, Rieke | Saintigny, Pierre | Harlé, Alexandre | Vacirca, Davide | Barberis, Massimo | Gilson, Pauline | Roma, Cristin | Saitta, Alexandra | Smith, Ewan | Consales Barras, Floriane | Ripol, Lucia | Fritzsche, Martin | Marques, Ana, Claudia | Alkodsi, Amjad | Marin, Ray | Normanno, Nicola | Grimm, Christoph | Müllauer, Leonhard | Harter, Philipp | Pignata, Sandro | Gonzalez-Martin, Antonio | Denison, Ursula | Fujiwara, Keiichi | Vergote, Ignace | Colombo, Nicoletta | Willig, Adrian | Pujade-Lauraine, Eric | Just, Pierre-Alexandre | Ray-Coquard, Isabelle | Xu, Zhenyu

Edité par CCSD ; Cell Press -

International audience. Highlights d Implementation hurdles restrict adoption of HRD testing, a PARPi response biomarker d GIInger leverages HRD-induced genome scarring from lowcoverage sequencing data d GIInger accurately stratifies ovarian cancer patients for PARPi treatment d GIInger is cost effective and seamlessly integrates into BRCA status workflows Authors

Suggestions

Du même auteur

GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles

Archive ouverte | Pozzorini, Christian | CCSD

International audience. Homologous recombination deficiency (HRD) is a predictive biomarker for poly(ADP-ribose) polymerase 1 inhibitor (PARPi) sensitivity. Routine HRD testing relies on identifying BRCA mutations, ...

Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

Archive ouverte | Harter, Philipp | CCSD

International audience

Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics

Archive ouverte | Quesada, Stanislas | CCSD

International audience. Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified h...

Chargement des enrichissements...